SOURCE: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc.

March 26, 2015 08:30 ET

PetLife Pharmaceuticals Provides Shareholder Update

LOS ANGELES, CA--(Marketwired - Mar 26, 2015) - PetLife Pharmaceuticals, Inc. (OTC PINK: PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today issued the following Special Letter to Shareholders:

"Dear Fellow Shareholder,

As the Chief Executive Officer of PetLife Pharmaceuticals (OTC PINK: PTLF), I wanted to take this time to reach out to our shareholders and provide an update on our company. Our vision to provide a new generation of veterinary cancer medications and nutraceuticals remains intact. As we continue to develop our technology, prepare for commercialization and strengthen our balance sheet, 2015 promises to be a watershed year for PetLife and its shareholders.

Even though we have been very quiet the past several months in the public arena there has been much progress going on behind the scenes. Although we had an unexpected funding delay in the last quarter of 2014, we now have new potential funding partners with whom we are negotiating to secure the necessary capital to carry the company forward and begin the FDA process for our revolutionary Escozine for Pets applications. We also experienced a delay in filing our audits and have made the necessary changes and anticipate completing the required annual 10-K and quarterly filings in the second quarter of 2015. This will bring the company fully compliant and should enable us to relist on the OTCQB, after filing the necessary paperwork.

Regular updates with veterinarians and individual pet owners indicates profound results from the product such as prolonging the life of pets, improving quality of life and tumor remission. You will find these testimonies on our website at www.petlifepharma.com. Buddy, the Golden Retriever, is doing well. He was diagnosed with an aggressive anal cancer and given only a few months to live well over a year ago. Bootsie, the 18 year old feline with lung cancer, is also doing well. The veterinarians in the Dominican Republic are continuing with the research and development of our injectable version and are experiencing very promising results with a variety of cancerous tumors in cats and dogs.

I want to thank you for your support. I have been working on the Polarization technology, which drives the potency of the Blue Scorpion extract, for more than 30 years. With the positive results we have been experiencing, I firmly believe our products will enhance the lives of pets in a positive manner and will be validated globally. We anticipate that our products will become leading products in the coming years and that we will gain market share in the veterinary over-the-counter medication sector that has $13 billion in revenue, in the US alone.

We thank you, our shareholders, for your support and trust and look forward to keeping you updated on our progress. 

Sincerely,

Arthur Mikaelian
Chief Executive Officer
 PetLife Pharmaceuticals"

About PetLife Pharmaceuticals

PetLife Pharmaceuticals (OTC PINK: PTLF) (www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012, and a spinoff of Medolife Corp.

PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets -- Escozine for Pets™. It is based on the same patented 'Escozine for humans' formula that has been sold by affiliate Medolife in 40 countries, using a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.

PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology -- with the ultimate goal of preventing cancer, extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals is expected to reach over $58 billion in 2014 with over $13 billion being spent on over the counter medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospects and performance. The Company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Contact Information